Abstract: Method of treating autoimmune conditions are disclosed comprising administering to a mammalian subject IL-12 or an IL-12 antagonist. In certain preferred embodiments the autoimmune condition is one which is promoted by an increase in levels of IFN-&ggr; or TNF-&agr;. Suitable conditions for treatment include multiple sclerosis, systemic lupus erythematosus, rheumatoid arthritis, autoimmune pulmonary inflammation, Guillain-Barre syndrome, autoimmune thyroiditis, insulin dependent diabetes melitis and autoimmune inflammatory eye disease.
Type:
Grant
Filed:
February 25, 2000
Date of Patent:
December 14, 2004
Assignee:
Genetics Institute, LLC
Inventors:
John Leonard, Samuel Goldman, Richard O'Hara, Jr.
Abstract: Novel compounds are disclosed which inhibit the activity of phospholipase enzymes, particularly cytosolic phospholipase A2. Pharmaceutical compositions comprising such compounds and methods of treatment using such compositions are also disclosed.
Type:
Grant
Filed:
September 29, 2000
Date of Patent:
December 7, 2004
Assignee:
Genetics Institute, LLC
Inventors:
Jasbir S. Seehra, Neelu Kaila, John McKew, Frank Lovering, Jean E. Bemis, YiBin Xiang
Abstract: The invention relates to a humanized anti-B7-2 antibody that comprises a variable region of nonhuman origin and at least a portion of an immunoglobulin of human origin. The invention also pertains to methods of treatment for various autoimmune diseases, transplant rejection, inflammatory disorders and infectious diseases by administering humanized anti-B7-2 and/or anti-B7-1 antibodies.
Type:
Grant
Filed:
July 27, 2000
Date of Patent:
December 7, 2004
Assignee:
Genetics Institute, LLC
Inventors:
Man Sung Co, Maximiliano Vasquez, Beatriz Carreno, Abbie Cheryl Celniker, Mary Collins, Samuel Goldman, Andrea Knight, Denise O'Hara, Bonita Rup, Geertruida M. Veldman, Gary S. Gray
Abstract: The present invention relates to, inter alia, methods for inhibiting the interaction of the B-lymphocyte antigen, B7-2, with its natural ligand on the surface of an immune cell are disclosed. The methods comprise contacting the immune cell with an agent which inhibits B7-2 binding with its natural ligand, to thereby inhibit the interaction. Examples of such agents are provided, and include a soluble form of B7-2, an antibody that recognized B7-2. The method may also include contacting the immune cell with an agent that blocks the interaction of B7-1 with its natural ligand. Further, the method may include contacting the immune cell with an immunomodulating agent, for example, an antibody reactive with CD28, an antibody reactive with CTLA4, an antibody reactive with a cytokine, a CTLA4Ig fusion protein, a CD28Ig fusion protein, and an immunosuppressive drug. Both in vivo and in vitro applications of the method are disclosed.
Type:
Grant
Filed:
October 22, 1999
Date of Patent:
November 30, 2004
Assignees:
Dana-Farber Cancer Institute, Inc., Genetics Institute, LLC
Inventors:
Gordon J. Freeman, Lee M. Nadler, Gary S. Gray
Abstract: The present invention provides for crystalline cPLA2. The crystal structure of cPLA2 has also been solved using such material. Models based upon such crystal structure are also provided. Methods of identifying inhibitors of cPLA2 activity and membrane binding using such models are also disclosed.
Type:
Grant
Filed:
February 15, 1999
Date of Patent:
October 5, 2004
Assignee:
Genetics Institute, LLC
Inventors:
Andrea Dessen, William S. Somers, Mark L. Stahl, Jasbir S. Seehra
Abstract: Methods and compositions are provided for the treatment of articular cartilage defects and disease involving the combination of tissue, such as osteochondral grafts, with active growth factor. The active growth factor is preferably a composition containing at least one bone morphogenetic protein and a suitable carrier. The method results in the regeneration of functional repair of articular cartilage tissue.
Type:
Application
Filed:
February 18, 2004
Publication date:
September 30, 2004
Applicant:
Genetics Institute, LLC
Inventors:
Renwen Zhang, Diane Peluso, Elisabeth Morris
Abstract: The use of interleukin-11 to prevent, to ameliorate, and to treat a gastrointestinal disorder in a mammal in need of such treatment is disclosed.
Type:
Application
Filed:
February 10, 2004
Publication date:
August 19, 2004
Applicants:
Genetics Institute, LLC, Catholic University
Inventors:
James C. Keith, Theo L. Peeters, Inge Depoortere, G. Van Asche
Abstract: Compositions of proteins with tendon/ligament-like tissue inducing activity are disclosed. The compositions are useful in the treatment of tendinitis and tendon or ligament defects and in related tissue repair.
Type:
Application
Filed:
February 18, 2004
Publication date:
July 29, 2004
Applicants:
Genetics Institute, LLC, President and Fellows of Harvard College
Inventors:
Anthony J. Celeste, John M. Wozney, Vicki A. Rosen, Neil M. Wolfman, Gerald H. Thomsen, Douglas A. Melton
Abstract: Novel serine/threonine receptor proteins and BMP receptor proteins are disclosed, as well as DNA molecules encoding said proteins and methods of using the receptor proteins. Further disclosed are truncated BMP receptor proteins and molecules which act as ligands to said BMP receptor proteins.
Type:
Application
Filed:
June 23, 2003
Publication date:
July 22, 2004
Applicant:
Genetics Institute, LLC.
Inventors:
John M. Wozney, Anthony J. Celeste, R. Scott Thies, Noboru Yamaji
Abstract: Methods are provided for purification of Factor VIII polypeptides by immunoaffinity chromatography and ion exchange chromatography, in which the eluate from the immunoaffinity column is diluted with a solution comprising higher salt concentration, or lower non-polar agent concentration than that of the elution solution, prior to passing the diluted solution through the ion exchange column. The methods result in improved purification without significant yield loss.
Type:
Application
Filed:
December 3, 2003
Publication date:
May 6, 2004
Applicant:
Genetics Institute, LLC
Inventors:
Brian D. Kelley, Suresh Vunnum, Johanna Dalborg, Anna Petersson
Abstract: The present invention relates to methods and compositions for the modulation of restenosis and stenosis characterized by constrictive vascular remodeling and neointimal formation, in a subject, by administering a P-selectin antagonist. The invention further provides methods for modulating leukocyte recruitment, cell to cell adhesion, and cell adhesion to blood vessels in a subject by administering soluble P-selectin ligand, an anti-P-selectin ligand antibody, or an anti-P-selectin antibody. The invention also provides methods for identifying compounds capable of modulating restenosis.
Type:
Application
Filed:
May 7, 2003
Publication date:
May 6, 2004
Applicants:
Genetics Institute, LLC, Montreal Heart Institute of Montreal
Inventors:
Anjali Kumar, Robert G. Schaub, Jean-Francois Tanguay, Yahye Merhi
Abstract: Methods and compositions are provided for the treatment of articular cartilage defects and disease involving the combination of tissue, such as osteochondral grafts, with active growth factor. The active growth factor is preferably a composition containing at least one bone morphogenetic protein and a suitable carrier. The method results in the regeneration of functional repair of articular cartilage tissue.
Type:
Grant
Filed:
January 28, 2000
Date of Patent:
April 27, 2004
Assignee:
Genetics Institute, LLC.
Inventors:
Renwen Zhang, Diane Peluso, Elisabeth Morris
Abstract: The use of interleukin-11 to prevent, to ameliorate, and to treat a gastrointestinal disorder in a mammal in need of such treatment is disclosed.
Type:
Grant
Filed:
August 1, 2001
Date of Patent:
April 20, 2004
Assignees:
Genetics Institute, LLC, Catholic University
Inventors:
James C. Keith, Jr., Theo L. Peeters, Inge Depoortere, G. Van Asche
Abstract: Compositions of proteins with tendon/ligament-like tissue inducing activity are disclosed. The compositions are useful in the treatment of tendinitis and tendon or ligament defects and in related tissue repair.
Type:
Grant
Filed:
August 31, 2001
Date of Patent:
April 13, 2004
Assignee:
Genetics Institute, LLC.
Inventors:
Anthony J. Celeste, John M. Wozney, Vicki A. Rosen, Neil M. Wolfman, Gerald H. Thomsen, Douglas A. Melton
Abstract: Method of treating autoimmune conditions are disclosed comprising administering to a mammalian subject IL-12 or an IL-12 antagonist. In certain preferred embodiments the autoimmune condition is one which is promoted by an increase in levels of IFN-&ggr; or TNF-&agr;. Suitable conditions for treatment include multiple sclerosis, systemic lupus erythematosus, rheumatoid arthritis, autoimmune pulmonary inflammation, Guillain-Barre syndrome, autoimmune thyroiditis, insulin dependent diabetes melitis and autoimmune inflammatory eye disease.
Type:
Grant
Filed:
February 25, 2000
Date of Patent:
March 16, 2004
Assignee:
Genetics Institute, LLC
Inventors:
John Leonard, Samuel Goldman, Richard O'Hara, Jr.
Abstract: Aggrecanase proteins and the nucleotides sequences encoding them as well as processes for producing them are disclosed. Methods for developing inhibitors of the aggrecanase enzymes and antibodies to the enzymes for treatment of conditions characterized by the degradation of aggrecan are also disclosed.
Type:
Grant
Filed:
October 18, 2001
Date of Patent:
February 10, 2004
Assignee:
Genetics Institute, LLC
Inventors:
Lisa A. Racie, Natalie C. Twine, Michael J. Agostino, Neil Wolfman, Elisabeth A. Morris
Abstract: Methods are provided for purification of Factor VIII polypeptides by immunoaffinity chromatography and ion exchange chromatography, in which the eluate from the immunoaffinity column is diluted with a solution comprising higher salt concentration, or lower non-polar agent concentration than that of the elution solution, prior to passing the diluted solution through the ion exchange column. The methods result in improved purification without significant yield loss.
Type:
Grant
Filed:
December 29, 2000
Date of Patent:
January 27, 2004
Assignee:
Genetics Institute, LLC
Inventors:
Brian D. Kelley, Suresh Vunnum, Johanna Dalborg, Anna Petersson